Market insight in association witH
Phosphorus and BioIQ announce partnership for at-home Covid-19 testing kits
According to GlobalData, so far, the US has performed 76 tests per million people. Despite having one of the largest numbers of Covid-19 cases in the world, the US testing rate has been one of the lowest. In order to contain the pandemic, various companies have started to develop at-home Covid-19 testing kits.
BioIQ, a healthcare engagement and clinical adherence technology platform company, and Phosphorus Diagnostic LLC, a medical device company, announced a partnership to provide at-home saliva-based testing kits. The joint solution for an at-home testing kit includes Phosphorus’ at-home Covid-19 saliva test kit, which uses the Oragene•Dx (OGD-510) saliva collection device that enables a fully unsupervised collection, and the BioIQ health technology platform for digital symptom assessment and follow-up care navigation.
In order to receive an at-home saliva testing kit, patients have to complete a medical questionnaire, which will be reviewed by an independent physician in order to determine eligibility. Once approved, the patient will receive the testing kit, and after the laboratory receives the sample, results will be available to consumers within 48 hours, along with the consultation with medical personnel.
The at-home testing approach will enable patients to be tested in the safety of their own homes, greatly eliminating infection exposure. At-home testing solutions will not only provide a better alternative to on-site testing of Covid-19, but greatly increase the number of people who have been tested. Furthermore, if testing results prove to be consistently accurate combined with a significant decrease of exposure risk to Covid-19, at-home testing kits will become an important step towards fighting the pandemic.
For more insight and data, visit GlobalData's Medical Intelligence Centre
Share this article